The likelihood of the Indian government buying vaccines from Pfizer and Moderna is very less as the domestic output of vaccines has been rising.
However, India has managed to expand its vaccine production capacity and meet the demand. Serum Institute of India is manufacturing more than 20 crore doses of Covisheild per month. In comparison, Bharat Biotech is able to produce three crore doses of Covaxin and is expected to ramp up the supply in the coming months. Sources have told that the current output is likely enough to meet the demand, and hence India would no longer buy the vaccines from foreign manufacturers. Moreover, the local vaccines are easier to store and are more affordable.